Boston Scientific BSX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.34B+99.3% | $670M+19.2% | $755M+61.3% | $795M+147% | $672M+36.3% | ||
| $351M+8.0% | $365M+4.9% | $342M+11.8% | $336M+8.0% | $325M+6.9% | ||
| $83M+12.2% | $71M+2.9% | $79M+16.2% | $75M+13.6% | $74M+17.5% | ||
| $117M+9.3% | $98M+8.9% | $32M-3.0% | $32M-71.9% | $107M-6.1% | ||
| $177M+62.4% | $50M— | $94M+70.9% | —— | $109M-12.1% | ||
| -$512M-33.0% | $285M-26.0% | $165M— | $231M— | -$385M+14.4% | ||
| $27M+486% | $20M+100% | —— | $79M+558% | -$7M-75.0% | ||
| $348M-35.7% | $1.36B-6.3% | $1.34B+34.0% | $1.29B+58.2% | $541M+230% | ||
| $177M-5.3% | $351M+26.7% | $181M+1.1% | $157M+1.3% | $187M+4.5% | ||
| $523M+119% | $89M-97.4% | $256M-77.3% | $1.01B+2,002% | $239M+409% | ||
| -$591M-18.2% | -$512M+86.2% | -$502M+64.8% | -$1.13B-315% | -$500M-75.4% | ||
| -$260M-212% | -$184M-186% | -$104M-1,586% | -$340M-1,517% | $233M-85.1% | ||
| $0-100% | $3M+133% | $0— | $2M+300% | $39M+657% | ||
| -$504M-261% | $671M+133% | $735M+278% | —— | $314M-78.2% | ||
| —— | $79.75M+27.6% | $79.75M+27.6% | $79.75M+27.6% | $79.75M+27.6% | ||
| —— | $140.25M-14.5% | $140.25M-14.5% | $140.25M-14.5% | $140.25M-14.5% | ||
| -$30M-700% | $7M+800% | $11M+148% | -$5M-350% | $5M-70.6% | ||
| -$351M-956% | -$22M+72.5% | $69M— | -$90M— | $41M+32.3% | ||
| $158M+664% | —— | —— | $219M+598% | -$28M-1,300% | ||
| $109M+41.6% | —— | —— | $31M-56.3% | $77M+40.0% | ||
| $2M-97.5% | $5M-90.2% | $9M— | $37M— | $81M— | ||
| -$48M-1,500% | -$73M-1,117% | -$4M+20.0% | -$4M+20.0% | -$3M+57.1% | ||
| -$61M-179% | $74M+363% | $70M-44.0% | $33M-54.8% | $77M+16.7% | ||
| $0-100% | $209M— | $7M— | $6M— | $36M+44.0% | ||
| $85M-28.0% | $3M-25.0% | $5M+66.7% | $5M+150% | $118M+51.3% | ||
| $0-100% | —— | —— | —— | $1.56B-27.4% | ||
| $3M+130% | $9M+3,700% | -$1M-300% | $9M+3,700% | -$10M-3,900% | ||
| $0+100% | —— | —— | —— | -$192M— | ||
| $81M-29.6% | $20M-28.6% | $115M+19.8% | $32M+23.1% | $115M+43.8% | ||
| $259M-76.1% | $0— | $12M— | $500M— | $1.08B+115% | ||
| —— | $29.75M+1.7% | $29.75M+1.7% | $29.75M+1.7% | $29.75M+1.7% | ||
| $171M-51.7% | $1.01B-14.1% | $1.16B+41.2% | $1.13B+71.6% | $354M+2,460% | ||
| $171M-51.7% | $1.01B-14.1% | $1.16B+41.2% | $1.13B+71.6% | $354M+2,460% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Boston Scientific generate?
- Boston Scientific (BSX) generated $4.3B in operating cash flow over the trailing twelve months.
- What is Boston Scientific's free cash flow?
- After $866.0M of capital expenditures, Boston Scientific's free cash flow was $3.5B over the trailing twelve months, up 15.3% year over year.
- Where does Boston Scientific's cash flow data come from?
- Every line is extracted from Boston Scientific's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
